Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07265284 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Name: A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis — clinical trial record (NCT07265284)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

Started2025-12-03

View on ClinicalTrials.gov ↗

Record status

This record was last updated December 22, 2025 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-12-19

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-12-31→confirmed 2025-12-03

Study sitesdetails revised at 1 of 1 site

2025-11-24

Original filing

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

7 trials monitored

See 1 trial at risk

Psoriasis

418 trials monitored

See 17 trials at risk

The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.

Trial Details

NCT Number	NCT07265284
Lead Sponsor	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Conditions	Psoriasis
Enrollment	104 participants
Start Date	2025-12-03
Primary Completion	2026-09-30 (estimated)
Study Completion	2029-01-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-22